Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Keros Therapeutics is a clinical-stage biopharmaceutical company developing novel TGF-β pathway therapeutics for disorders affecting blood, bone, muscle, and cardiovascular tissues. Its key products target pulmonary arterial hypertension, neuromuscular diseases, and hematologic conditions like MDS and myelofibrosis. The company's approach leverages proprietary protein therapeutics to modulate tissue growth, repair, and maintenance, aiming to address unmet medical needs with potentially disease-modifying treatments.
This description was generated via AI from an annual report. Updated about 1 year ago.